Clinically, the low expression of GnRHR or FOXO1 and high expression of AKT correlate with tumor aggressiveness and unfavorable clinical outcomes, suggesting their utility as novel prognostic biomarkers in EOC patients. This evidence concerns the gene AKT1 and neoplasm.